Recital 15, Regulation (EU) 2020/1043

In forcesince 15 Jul 2020

To generate the robust clinical evidence necessary to support applications for marketing authorisation of medicinal products intended to treat or prevent COVID-19 multi-centre clinical trials involving several Member States will need to be conducted.